Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol

BACKGROUND: Although enzyme replacement therapy with agalsidase beta resulted in a variety of clinical benefits, life‐long biweekly intravenous infusion may impact on patients’ quality of life. Moreover, regular infusions are time‐consuming: although a stepwise shortening of infusion duration is all...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccio, Eleonora, Zanfardino, Mario, Franzese, Monica, Capuano, Ivana, Buonanno, Pasquale, Ferreri, Lucia, Amicone, Maria, Pisani, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172210/
https://www.ncbi.nlm.nih.gov/pubmed/33755336
http://dx.doi.org/10.1002/mgg3.1659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172210/
https://www.ncbi.nlm.nih.gov/pubmed/33755336
http://dx.doi.org/10.1002/mgg3.1659

Ejemplares similares